A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
about
A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases
description
clinical trial
@en
klinisch onderzoek
@nl
name
A Randomised Phase II Trial of ...... ed NSCLC With Brain Metastases
@en
type
label
A Randomised Phase II Trial of ...... ed NSCLC With Brain Metastases
@en
prefLabel
A Randomised Phase II Trial of ...... ed NSCLC With Brain Metastases
@en
P6153
P1476
A Randomised Phase II Trial of ...... (NSCLC) With Brain Metastases
@en
P17
P1813
OUTRUN
@en
P3098
NCT03497767
P4844
P580
2019-03-01T00:00:00Z
P582
2021-09-01T00:00:00Z